Savara (SVRA) Cash from Financing Activities (2010 - 2026)
Savara's (SVRA) quarterly Cash from Financing Activities came in at -$195000.0 in Q1 2026, down 108.41% year-on-year from $2.3 million in Q1 2025, and down 100.14% on a QoQ basis from $135.6 million in Q4 2025.
Savara (SVRA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Cash from Financing Activities data on file, last reported at -$195000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 108.41% year-over-year to -$195000.0 in Q1 2026; TTM through Mar 2026 was $135.3 million, a 12.89% increase from a year earlier, with the FY2025 full-year figure at $137.8 million, up 17.2% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$195000.0, down from $135.6 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for SVRA reached as high as $135.6 million in Q4 2025 and fell as low as -$843000.0 in Q4 2024.
- Historically, Cash from Financing Activities has averaged $19.9 million across 5 years, with a median of $49000.0 in 2024.
- Across the five-year window, Cash from Financing Activities surged 7475600.0% in 2023 and slumped 189.09% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $1000.0 in 2022, then surged by 789400.0% to $7.9 million in 2023, then sank by 110.68% to -$843000.0 in 2024, then jumped by 16180.66% to $135.6 million in 2025, then sank by 100.14% to -$195000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$195000.0 in Q1 2026, $135.6 million in Q4 2025, and -$23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | -195,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -195,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Dec 31, 2025 | 135.56 Mn |
| Dec 31, 2025 | 135.56 Mn |
| Sep 30, 2025 | -23,000.00 |
| Sep 30, 2025 | -23,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | -843,000.00 |
| Dec 31, 2024 | -843,000.00 |
| Sep 30, 2024 | 118.32 Mn |
| Sep 30, 2024 | 118.32 Mn |
| Jun 30, 2024 | 55,000.00 |
| Jun 30, 2024 | 55,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 7.90 Mn |
| Dec 31, 2023 | 7.90 Mn |